Observational Registry Following Heart Conditions Through Routine Cardiac Testing
Collects routine heart test results from people with heart failure, arrhythmias, or coronary artery disease.
Plain-language title generated from the registry record
Registry title: The Multicenter Cardiology Monitoring Platform Registry
Key facts
- Where
- Maastricht, NetherlandsSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 16 or older who were sent to a cardiology or genetics clinic with heart failure-like symptoms or for heart or heart-gene screening.
- Age
- 16 years or older
- Sex
- All sexes
Main reasons for not taking part
- Unwilling to take part
- Unable to give written informed consent, for example because of language barriers or severe intellectual disability
Read by machine on 12 November 2026.
Where in Netherlands
- Maastricht UMCMaastricht, NetherlandsContact: Jerremy WeertsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Maastricht University Medical Center
- Trial code
- NCT04976348
- Record updated
- 19 October 2026
- Original description
The multicenter Cardiology Monitoring Platform registry (mCMP-registry) is a prospective observational registry including multi-omics (diagnostic) measurements performed as part of routine clinical care, bio-banking (optional), and yearly questionnaires (optional).Read full original descriptionShow less
The Multicenter Cardiology Monitoring Platform Registry (mCMP-registry)
The multicenter Cardiology Monitoring Platform registry (mCMP-registry) is a prospective observational registry including multi-omics (diagnostic) measurements performed as part of routine clinical care, bio-banking (optional), and yearly questionnaires (optional).
It's objective is to optimize (early) diagnosis and risk-stratification of (early) cardiovascular diseases, specifically cardiomyopathy phenotypes, arrhythmias, and coronary artery disease, and to create a better understanding of underlying pathophysiological processes.
Inclusion: Referred to the cardiology or genetic department for heart failure like symptoms (as stated in the ESC 2016 Guidelines(3)) or for cardiac/cardiogenetic screening; Age ≥16 years.
Exclusion: Unwillingness to participate or unable to give written informed consent (e.g. due to language barriers or severe intellectual disability).